Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Drewe

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Clinical Pathology|February 28, 2002
Clinically useful monoclonal antibodies in treatmentE Drewe, R J Powell
Rheumatology (Oxford, England)|February 22, 2003
Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patientsE Drewe, E M McDermott, P T Powell, et al.
Rheumatology (Oxford, England)|August 19, 2004
Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndromeE Drewe, M L Huggins, A G Morgan, et al.
Journal of Autoimmunity|February 1, 1993
Cross-reactive idiotypes on high affinity IgG class human monoclonal thyroglobulin autoantibodiesP J Delves, S M McLachlan, E Drewe, et al.
Rheumatology (Oxford, England)|November 17, 2005
Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1AM L Nowlan, E Drewe, H Bulsara, et al.
Clinical and Experimental Immunology|April 23, 2019
Patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulationO H Negm, S Singh, W Abduljabbar, et al.
Clinical and Experimental Immunology|July 22, 2010
NOD2 polymorphisms in clinical phenotypes of common variable immunodeficiency disordersK Packwood, E Drewe, E Staples, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Clinical Pathology|February 28, 2002
Clinically useful monoclonal antibodies in treatmentE Drewe, R J Powell
Rheumatology (Oxford, England)|February 22, 2003
Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patientsE Drewe, E M McDermott, P T Powell, et al.
Rheumatology (Oxford, England)|August 19, 2004
Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndromeE Drewe, M L Huggins, A G Morgan, et al.
Journal of Autoimmunity|February 1, 1993
Cross-reactive idiotypes on high affinity IgG class human monoclonal thyroglobulin autoantibodiesP J Delves, S M McLachlan, E Drewe, et al.
Rheumatology (Oxford, England)|November 17, 2005
Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1AM L Nowlan, E Drewe, H Bulsara, et al.
Clinical and Experimental Immunology|April 23, 2019
Patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulationO H Negm, S Singh, W Abduljabbar, et al.
Clinical and Experimental Immunology|July 22, 2010
NOD2 polymorphisms in clinical phenotypes of common variable immunodeficiency disordersK Packwood, E Drewe, E Staples, et al.
Pageof 1